BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26313789)

  • 1. Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
    Jiménez-Triana CA; Castelán-Martínez OD; Rivas-Ruiz R; Jiménez-Méndez R; Medina A; Clark P; Rassekh R; Castañeda-Hernández G; Carleton B; Medeiros M;
    Medicine (Baltimore); 2015 Aug; 94(34):e1413. PubMed ID: 26313789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.
    Minzi OMS; Lyimo TE; Furia FF; Marealle AI; Kilonzi M; Bwire GM; Malichewe C
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):69. PubMed ID: 32967726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
    Kidera Y; Kawakami H; Sakiyama T; Okamoto K; Tanaka K; Takeda M; Kaneda H; Nishina S; Tsurutani J; Fujiwara K; Nomura M; Yamazoe Y; Chiba Y; Nishida S; Tamura T; Nakagawa K
    PLoS One; 2014; 9(7):e101902. PubMed ID: 25020203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
    Prasaja Y; Sutandyo N; Andrajati R
    Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer.
    Sugisaki T; Aoyama T; Kawakami K; Yokokawa T; Kobayashi K; Suzuki W; Ogura M; Ichimura T; Chin K; Yamaguchi K; Hanaoka S; Hayashi H; Yamaguchi M
    Pharmazie; 2022 Feb; 77(2):85-88. PubMed ID: 35209969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
    Fujieda M; Matsunaga A; Hayashi A; Tauchi H; Chayama K; Sekine T
    J Toxicol Sci; 2009; 34 Suppl 2():SP251-7. PubMed ID: 19571477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
    Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
    Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal tolerance to cisplatin in patients 70 years and older.
    Cubillo A; Cornide M; López JL; Molina R; Feliu J; Espinosa E; Zamora P; de Castro J; Ordoñez A; González Barón M
    Am J Clin Oncol; 2001 Apr; 24(2):192-7. PubMed ID: 11319297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors.
    Arga M; Oguz A; Pinarli FG; Karadeniz C; Citak EC; Emeksiz HC; Duran EA; Soylemezoglu O
    Pediatr Int; 2015 Jun; 57(3):406-13. PubMed ID: 25441241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
    Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
    J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study.
    Matsui M; Saito Y; Yamaoka S; Yokokawa Y; Morikawa Y; Makimoto A; Yuza Y
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):379-381. PubMed ID: 29683958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis.
    Miyoshi T; Hayashi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C; Nakano T; Egawa T
    Support Care Cancer; 2022 Apr; 30(4):3345-3351. PubMed ID: 34984552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
    JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide nephrotoxicity in pediatric cancer patients.
    Lee BS; Lee JH; Kang HG; Hahn H; Lee JH; Shin HY; Ha IS; Cheong HI; Ahn HS; Choi Y
    Pediatr Nephrol; 2001 Oct; 16(10):796-9. PubMed ID: 11605785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.